WO1998005331A3 - Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators - Google Patents

Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators Download PDF

Info

Publication number
WO1998005331A3
WO1998005331A3 PCT/US1997/013605 US9713605W WO9805331A3 WO 1998005331 A3 WO1998005331 A3 WO 1998005331A3 US 9713605 W US9713605 W US 9713605W WO 9805331 A3 WO9805331 A3 WO 9805331A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonist
diabetes
prevention
treatment
cardiovascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/013605
Other languages
French (fr)
Other versions
WO1998005331A2 (en
Inventor
James R Paterniti
Michael R Briggs
Ranjan Mukherjee
Johan Auwerx
Bart Stael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Priority to AU40507/97A priority Critical patent/AU4050797A/en
Priority to EP97938101A priority patent/EP0930882A2/en
Publication of WO1998005331A2 publication Critical patent/WO1998005331A2/en
Publication of WO1998005331A3 publication Critical patent/WO1998005331A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to methods and compositions for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPARη agonist and a PPARα agonist or a compound which activates both PPARη and PPARα. A preferred PPARη agonist is a thiazolidinedione compound, including BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and congeners, analogs, derivatives and pharmaceutically acceptable salts thereof. A preferred PPARα agonist is a fibrate compound including gemfibrozil, fenofibrate, bezofibrate, clofibrate, ciprofibrate, and analogs, derivatives and pharmaceutically acceptable salts thereof.
PCT/US1997/013605 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators Ceased WO1998005331A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU40507/97A AU4050797A (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
EP97938101A EP0930882A2 (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2294996P 1996-08-02 1996-08-02
US60/022,949 1996-08-02

Publications (2)

Publication Number Publication Date
WO1998005331A2 WO1998005331A2 (en) 1998-02-12
WO1998005331A3 true WO1998005331A3 (en) 1998-05-07

Family

ID=21812265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013605 Ceased WO1998005331A2 (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Country Status (3)

Country Link
EP (1) EP0930882A2 (en)
AU (1) AU4050797A (en)
WO (1) WO1998005331A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7030106B2 (en) 2001-01-26 2006-04-18 Schering Corporation Sterol absorption inhibitor compositions
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
JP4798814B2 (en) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド Use of exendin and its agonists to reduce food intake
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
FR2774591B1 (en) * 1998-02-12 2000-05-05 Lipha PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
ES2226377T3 (en) 1998-05-11 2005-03-16 Takeda Chemical Industries, Ltd. DERIVATIVES OF OXIIMINO-ALCALINO ACID WITH HYPOGLUCEMIC AND HYPOLIPIDEMIC ACTIVITY.
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
AU4250200A (en) * 1999-04-19 2000-11-02 Coelacanth Corporation Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
AU4652600A (en) * 1999-04-23 2000-11-10 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptorgamma using differential gene expression
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
WO2001044512A2 (en) * 1999-12-16 2001-06-21 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptor gamma using differential gene expression
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
JP4879433B2 (en) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク Compounds and compositions for delivering active agents
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
MXPA02007603A (en) * 2000-03-09 2003-02-24 Aventis Pharma Gmbh Therapeutic uses of ppar mediators.
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
EA200300028A1 (en) * 2000-06-16 2003-04-24 Смитклайн Бичам Плс TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE
IT1317885B1 (en) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti USE OF FIBRATES FOR THE PREPARATION OF A USEFUL DRUG IN THE TREATMENT OF CONGESTIAL HEART INSUFFICIENCY.
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1372632A1 (en) * 2001-02-15 2004-01-02 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
MXPA03007284A (en) 2001-02-15 2003-12-04 Pfizer Prod Inc Ppar agonists.
BRPI0208384B1 (en) 2001-03-28 2016-05-31 Merck Sharp & Dohme enantioselective synthesis of azetidinone intermediate compounds
WO2002087580A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Abc expression promoters
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
ITRM20020014A1 (en) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti DERIVATIVES OF A-PHENYLTHIOCARBOXYL AND A-PHYLYOXYCARBOXYL ACIDS USEFUL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF
CA2481371A1 (en) * 2002-03-11 2003-09-18 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US7811593B2 (en) * 2002-03-25 2010-10-12 Jian Luo Pharmaceutical composition with combined active agents and methods for using the same
EP1388351A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of fibrate to treat weight gain associated with rosiglitazone treatment
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
DK1567493T3 (en) 2002-11-26 2009-06-08 Pfizer Prod Inc Phenyl-substituted piperidine compounds for use as PPAR activators
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR20150127599A (en) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 Compositions and methods for treating non-alcoholic steatohepatitis
PL3004138T3 (en) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP2016534043A (en) 2013-10-09 2016-11-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for down-regulation of pro-inflammatory cytokines

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305890A2 (en) * 1987-09-01 1989-03-08 Roche Diagnostics GmbH Use of bezafibrate for the treatment of diabetes
JPH05194209A (en) * 1992-01-21 1993-08-03 Grelan Pharmaceut Co Ltd Hemangioendothelial cell function improver
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305890A2 (en) * 1987-09-01 1989-03-08 Roche Diagnostics GmbH Use of bezafibrate for the treatment of diabetes
JPH05194209A (en) * 1992-01-21 1993-08-03 Grelan Pharmaceut Co Ltd Hemangioendothelial cell function improver
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARNETT ET AL.: "Effect of Clofibrate on Glucose Tolerance in Maturity Onset Diabetes", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 4, 1977, pages 455 - 458, XP002045778 *
DATABASE WPI Section Ch Week 9335, Derwent World Patents Index; Class B05, AN 93-278192, XP002045779 *
KARAM J H: "TYPE II DIABETES AND SYNDROME X PATHOGENESIS AND GLYCEMIC MANAGEMENT", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 21, no. 2, 1 June 1992 (1992-06-01), pages 329 - 350, XP000605976 *
LEHMANN J M ET AL: "AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARGAMMA)", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 22, 2 June 1995 (1995-06-02), pages 12953 - 12956, XP000577082 *
LENHARD J M ET AL: "ANALYSIS OF THIAZOLIDINEDIONE, BIGUANIDE AND RETINOID EFFECTS ON ADIPOGENESIS AND THE NUCLEAR RECEPTORS PPARgamma AND RXR", DIABETOLOGIA, SUPPLEMENT, vol. 39, 5 September 1996 (1996-09-05), pages A234, XP000613679 *
WILLSON T M ET AL: "THE STRUCTURE-ACTIVITY RELATIONSHIP BETWEEN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISM AND THE ANTIHYPERGLYCEMIC ACTIVITY OF THIAZOLIDINEDIONES", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 3, 2 February 1996 (1996-02-02), pages 665 - 668, XP000613613 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7425557B2 (en) 1998-06-19 2008-09-16 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7030106B2 (en) 2001-01-26 2006-04-18 Schering Corporation Sterol absorption inhibitor compositions
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7368563B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368562B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7378518B2 (en) 2003-03-07 2008-05-27 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

Also Published As

Publication number Publication date
AU4050797A (en) 1998-02-25
EP0930882A2 (en) 1999-07-28
WO1998005331A2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
US12053456B2 (en) Pharmaceutical compositions for combination therapy
CA2328730C (en) Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
Millan N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review
TWI407955B (en) Prevention and/or treatment of hyperlipidemia
US20200061028A1 (en) Pharmaceutical compositions for combination therapy
WO2004066990B1 (en) Methods of treating lower urinary tract disorders using sodium channel modulators
CA2581298A1 (en) Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
WO1995017876A3 (en) 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps
WO1998048785A3 (en) Allelic polygene diagnosis of reward deficiency syndrome and treatment
CA2145521A1 (en) Method and composition for the treatment of parkinson's disease
Wu et al. l-α-Aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: A microdialysis study in freely moving rats
NO322314B1 (en) Pharmaceutical preparation, comprising multiple containers, as well as the use of troglitazone, pioglitazone and / or BRL-49653 in the manufacture of a medicament.
FR2513117A1 (en) PARKINSON'S DISEASE AGENT COMPRISING THREO-3, 4-DIHYDROXYPHENYLSERINE AND A DECARBOXYLASE INHIBITOR
Cooper Ketoprofen in oral surgery pain: a review
AU2010224037A1 (en) Compositions and methods for prophylaxis and treatment of addictions
OA12549A (en) Method of treating of demyelinating diseases or conditions.
FR2530469A1 (en) ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION CONTAINING CAFFEINE
US8865747B2 (en) Pioglitazone for use in the treatment of adrenoleukodystrophy
US4540582A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
EP1405848A4 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
US6034110A (en) Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand
US11241420B2 (en) Compositions and methods for prophylaxis and treatment of addictions
AU714086B2 (en) Use of COMT inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
NZ337927A (en) Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (NIDDM) using specific retinoid compounds
NZ192255A (en) Analgesic composition containing paraacetaminophenol as potentiator and one of seven named analgesic drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997938101

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998508107

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997938101

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997938101

Country of ref document: EP